[前列腺癌筛查：尚无益处的确凿证据] - Suppr | 超能文献

[Prostate cancer screening: no proof of the benefit].

作者信息

Laplanche Agnès, Hill Catherine

出版信息

Presse Med. 2009 Oct;38(10):1393-5. doi: 10.1016/j.lpm.2009.07.001. Epub 2009 Aug 3.

DOI:10.1016/j.lpm.2009.07.001

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

[Prostate cancer screening: no proof of the benefit].[前列腺癌筛查：尚无益处的确凿证据]

Presse Med. 2009 Oct;38(10):1393-5. doi: 10.1016/j.lpm.2009.07.001. Epub 2009 Aug 3.

2

The science and art of prostate cancer screening.前列腺癌筛查的科学与艺术。

J Natl Cancer Inst. 2011 Mar 16;103(6):450-1. doi: 10.1093/jnci/djr047. Epub 2011 Feb 24.

3

Early-stage prostate cancer, PSA screening rates decline.早期前列腺癌，前列腺特异抗原筛查率下降。

Cancer. 2016 Mar 15;122(6):825. doi: 10.1002/cncr.29930.

4

Re: Public knowledge of benefits of breast and prostate cancer screening in Europe.关于：欧洲公众对乳腺癌和前列腺癌筛查益处的了解。

J Natl Cancer Inst. 2010 Mar 3;102(5):356; author reply 356-7. doi: 10.1093/jnci/djp516. Epub 2010 Jan 14.

5

Prostate-specific antigen screening in the United States vs in the European Randomized Study of Screening for Prostate Cancer-Rotterdam.美国与欧洲前列腺癌筛查随机研究-鹿特丹的前列腺特异性抗原筛查比较。

J Natl Cancer Inst. 2010 Mar 3;102(5):352-5. doi: 10.1093/jnci/djp533. Epub 2010 Feb 8.

6

Prostate specific antigen (PSA) testing as screening for prostate cancer: the current controversy.前列腺特异性抗原（PSA）检测用于前列腺癌筛查：当前的争议

Ann Oncol. 1998 Dec;9(12):1263-4. doi: 10.1023/a:1008435911379.

7

Re: prostate cancer screening in the randomized prostate, lung, colorectal, and ovarian cancer screening trial: mortality results after 13 years of follow-up.关于：在随机化前列腺、肺、结肠直肠和卵巢癌筛查试验中的前列腺癌筛查：13年随访后的死亡率结果

J Natl Cancer Inst. 2012 May 16;104(10):793; author reply 793-4. doi: 10.1093/jnci/djs205. Epub 2012 Apr 5.

8

[Detection of prostate cancer: yes or no?].[前列腺癌的检测：是与否？]

Bull Mem Acad R Med Belg. 2006;161(3-4):159-69.

9

Prostate cancer screening: and yet it moves!前列腺癌筛查：然而它仍在发展！

Asian J Androl. 2015 May-Jun;17(3):437-8. doi: 10.4103/1008-682X.143310.

10

Why are a high overdiagnosis probability and a long lead time for prostate cancer screening so important?为什么前列腺癌筛查的高过度诊断概率和长领先时间如此重要？

J Natl Cancer Inst. 2009 Mar 18;101(6):362-3. doi: 10.1093/jnci/djp028. Epub 2009 Mar 10.